| | |

Treatment Protocol of an 8-Year Survivor of Mesothelioma

Treatment Protocol of an 8-Year Survivor of Mesothelioma A new article in Scholars Journal of Medical Case Reports outlines the treatment protocol of an 8-year survivor of mesothelioma. Malignant pleural mesothelioma is difficult to treat. This aggressive cancer is caused by asbestos exposure and is resistant to most standard cancer therapies, including radiotherapy. Many people diagnosed with mesothelioma die within a few months to a year.

Paul Kraus is considered the longest documented survivor of mesothelioma in the world. He was diagnosed in 1997 and was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic lifestyle changes, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check.

Treating Epithelial-Type Malignant Pleural Mesothelioma

Malignant mesothelioma is a very aggressive cancer. Pleural mesothelioma is a type of cancer that develops from the thin layer of tissue that covers the lungs and chest wall. It can often take around 40 years for pleural mesothelioma to begin. Imaging studies such as X-rays or CT scans may help in the diagnosis, but a tissue biopsy usually confirms the disease.

In this latest article, a Moroccan team outlines the diagnosis and treatment protocol for an 8-year survivor of mesothelioma. The case is that of a former mine worker with malignant pleural mesothelioma. Although the 71-year-old patient worked in a field that might have exposed him to asbestos, his doctors did not immediately suspect mesothelioma. The patient was a former smoker who estimated around 45 packs/year. The patient’s brother died of cancer. And he also had a cousin who was followed for malignant mesothelioma.

At first, the patient went to a pulmonologist and a chest scan was done. Chest pain is one of the classic symptoms of mesothelioma, but it is also a symptom of many other types of heart, nerve, and respiratory problems. A CT scan of the man’s chest revealed pleural thickening of the right lung. This pleural thickening is another common symptom of mesothelioma, especially in people with a history of asbestos exposure.

Ultimately, the patient was diagnosed with a chest scan and a CT-guided biopsy. This revealed an epithelial-type mesothelium. First, the patient had a few tests to confirm cancer had not spread. Then, he had an abdominopelvic CT scan and bone scintigraphy. These confirmed that the cancer was limited to just one location.

Next, the patient received six cycles of chemotherapy of paclitaxel-carboplatin. Paclitaxel and carboplatin are the names of a chemotherapy combination. It’s also known as PC and CarboTaxo. The patient was then put under surveillance with a maintenance CT Scan every 4 months, then every 6 months. Each scan showed stable pleural thickening and no suspicious lesions.

CONCLUSION

Symptoms of pleural mesothelioma are frequently confused with symptoms of other, less severe respiratory diseases. Consequently, this confusion of symptoms frequently leads to a wrong diagnosis which can delay treatment and make the battle with pleural mesothelioma even more difficult.

Lead author, Dr. Khouchani of Cadi Ayyad University says, “Malignant mesothelioma is one of the most aggressive cancers, we recall the role of occupational and environmental exposure to asbestos in its genesis its prognosis is poor despite the development of new treatments including immunotherapy.”

A diagnosis of pleural mesothelioma can be devastating physically, emotionally, and financially. Advances in modern medicine have allowed for the improvement of mesothelioma treatment. There is no definitive cure for the disease. A variety of treatment options can extend the duration and quality of life for many people with mesothelioma.

Source:

Ballouk, F. Z., A. Sabiq, N. Kadri, I. Zaytoune, B. Mahrouch, M. Bennani, A. A. Agouzzal et al. “An 8-Year Survival of a Probable Pleural Mesothelium: A Case Report.” Sch J Med Case Rep 7 (2022): 642-646. https://saspublishers.com/media/articles/SJMCR_107_642-646.pdf

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…